208 related articles for article (PubMed ID: 6614006)
21. [Isolation and characteristics of hexosaminidase A and activator protein from human kidney].
Aronovich EL; Akhunov VS; Krasnopol'skaia KD
Biokhimiia; 1990 Jan; 55(1):43-51. PubMed ID: 2140519
[TBL] [Abstract][Full Text] [Related]
22. Plasma G
Blondel A; Kraoua I; Marcelino C; Khrouf W; Schlemmer D; Ganne B; Caillaud C; Fernández-Eulate G; Turki IBY; Dauriat B; Bonnefont-Rousselot D; Nadjar Y; Lamari F
Mol Genet Metab; 2023 Feb; 138(2):106983. PubMed ID: 36709536
[TBL] [Abstract][Full Text] [Related]
23. Complexing of glycolipids and their transfer between membranes by the activator protein for degradation of lysosomal ganglioside GM2.
Conzelmann E; Burg J; Stephan G; Sandhoff K
Eur J Biochem; 1982 Apr; 123(2):455-64. PubMed ID: 6210531
[TBL] [Abstract][Full Text] [Related]
24. Western blotting analysis of the beta-hexosaminidase alpha- and beta-subunits in cultured fibroblasts from cases of various forms of GM2 gangliosidosis.
Utsumi K; Tsuji A; Kase R; Tanaka A; Tanaka T; Uyama E; Ozawa T; Sakuraba H; Komaba Y; Kawabe M; Iino Y; Katayama Y
Acta Neurol Scand; 2002 Jun; 105(6):427-30. PubMed ID: 12027830
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of novel NBD-GM1 and NBD-GM2 for the transfer activity of GM2-activator protein by a FRET-based assay system.
Schwarzmann G; Wendeler M; Sandhoff K
Glycobiology; 2005 Dec; 15(12):1302-11. PubMed ID: 16079415
[TBL] [Abstract][Full Text] [Related]
26. Alpha-locus hexosaminidase genetic compound with juvenile gangliosidosis phenotype: clinical, genetic, and biochemical studies.
Johnson WG; Cohen CS; Miranda AF; Waran SP; Chutorian AM
Am J Hum Genet; 1980 Jul; 32(4):508-18. PubMed ID: 6772023
[TBL] [Abstract][Full Text] [Related]
27. The mutation mechanism causing juvenile-onset Tay-Sachs disease among Lebanese.
Hechtman P; Boulay B; Bayleran J; Andermann E
Clin Genet; 1989 May; 35(5):364-75. PubMed ID: 2527097
[TBL] [Abstract][Full Text] [Related]
28. Degradation of keratan sulfate by beta-N-acetylhexosaminidases in GM2-gangliosidosis.
Yutaka T; Okada S; Kato T; Yabuuhi H
Clin Genet; 1982 Mar; 21(3):196-202. PubMed ID: 6212169
[TBL] [Abstract][Full Text] [Related]
29. Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease.
Kodama T; Togawa T; Tsukimura T; Kawashima I; Matsuoka K; Kitakaze K; Tsuji D; Itoh K; Ishida Y; Suzuki M; Suzuki T; Sakuraba H
PLoS One; 2011; 6(12):e29074. PubMed ID: 22205997
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of 4-methylumbelliferyl-beta-D-N-acetylglucosamine-6-sulfate and its use in classification of GM2 gangliosidosis genotypes.
Bayleran J; Hechtman P; Saray W
Clin Chim Acta; 1984 Nov; 143(2):73-89. PubMed ID: 6239713
[TBL] [Abstract][Full Text] [Related]
31. Interaction of activating protein and surfactants with human liver hexosaminidase A and GM2 ganglioside.
Hechtman P; Kachra Z
Biochem J; 1980 Mar; 185(3):583-91. PubMed ID: 7387624
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic evaluation of GM2 gangliosidoses by ELISA using anti-GM2 ganglioside antibodies.
Tsuji D; Higashine Y; Matsuoka K; Sakuraba H; Itoh K
Clin Chim Acta; 2007 Mar; 378(1-2):38-41. PubMed ID: 17196574
[TBL] [Abstract][Full Text] [Related]
33. Differentiation of two variants of type-AB GM2-gangliosidosis using chromogenic substrates.
Li YT; Hirabayashi Y; Li SC
Am J Hum Genet; 1983 May; 35(3):520-2. PubMed ID: 6222647
[TBL] [Abstract][Full Text] [Related]
34. Hereditary heat-labile hexosaminidase B: a variant whose homozygotes synthesize a functional HEX A.
Navon R; Kopel R; Nutman J; Frisch A; Conzelmann E; Sandhoff K; Adam A
Am J Hum Genet; 1985 Jan; 37(1):138-46. PubMed ID: 3156493
[TBL] [Abstract][Full Text] [Related]
35. The human GM2 activator protein. A substrate specific cofactor of beta-hexosaminidase A.
Meier EM; Schwarzmann G; Fürst W; Sandhoff K
J Biol Chem; 1991 Jan; 266(3):1879-87. PubMed ID: 1824846
[TBL] [Abstract][Full Text] [Related]
36. Activating proteins for ganglioside GM2 degradation by beta-hexosaminidase isoenzymes in tissue extracts from different species.
Burg J; Banerjee A; Conzelmann E; Sandhoff K
Hoppe Seylers Z Physiol Chem; 1983 Jul; 364(7):821-9. PubMed ID: 6225718
[TBL] [Abstract][Full Text] [Related]
37. Nonuniform deficiency of hexosaminidase A in tissues and fluids of two unrelated individuals.
Thomas GH; Raghavan S; Kolodny EH; Frisch A; Neufeld EF; O'Brien JS; Reynolds LW; Miller CS; Shapiro J; Kazazian HH; Heller RH
Pediatr Res; 1982 Mar; 16(3):232-7. PubMed ID: 7063277
[TBL] [Abstract][Full Text] [Related]
38. Clinical and genetic variations in the syndrome of adult GM2 gangliosidosis resulting from hexosaminidase A deficiency.
Argov Z; Navon R
Ann Neurol; 1984 Jul; 16(1):14-20. PubMed ID: 6235771
[TBL] [Abstract][Full Text] [Related]
39. Biochemical and molecular aspects of late-onset GM2-gangliosidosis: B1 variant as a prototype.
Suzuki K; Vanier MT
Dev Neurosci; 1991; 13(4-5):288-94. PubMed ID: 1840099
[TBL] [Abstract][Full Text] [Related]
40. Late onset GM2 gangliosidosis: an alpha-locus genetic compound with near normal hexosaminidase activity.
Charrow J; Inui K; Wenger DA
Clin Genet; 1985 Jan; 27(1):78-84. PubMed ID: 3156697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
